Meningiomas in the first group are devoid of NF2 alterations and chromosomal instability; may feature AKT1, TRAF7, or KLF4 mutations; have the best prognosis; and are expected to respond to cytotoxic drugs. This evidence concerns the gene NF2 and meningioma.